Drug development: Illuminated targets. - Wikidata - awgldk - TriplyDB

Drug development: Illuminated targets.

Drug development: Illuminated targets.

http://www.wikidata.org/entity/Q48070946

about

Copper-uptake is critical for the down regulation of synapsin and dynamin induced by neocuproine: modulation of synaptic activity in hippocampal neurons.Antiepileptogenic Effect of Subchronic Palmitoylethanolamide Treatment in a Mouse Model of Acute Epilepsy.

P2860

Q41674930-3E9B5B9E-CAFA-4485-BE48-90207D63E5A0 Q52316988-556B3FF5-0489-4F62-BC5B-60B5B8B15759

P2860

Drug development: Illuminated targets.

http://www.wikidata.org/entity/Q48070946

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Drug development: Illuminated targets.

@en

Drug development: Illuminated targets.

@nl

type

label

Drug development: Illuminated targets.

@en

Drug development: Illuminated targets.

@nl

prefLabel

Drug development: Illuminated targets.

@en

Drug development: Illuminated targets.

@nl

P1433

Q48070946-1B26E128-CA17-44DE-9327-C219C9BF6348

P1476

Q48070946-8A5BD9B1-A558-4D7D-B40A-21E1B003035E

P2093

Q48070946-79300659-199E-412A-B27E-2BAC751C4FC5

P2860

Q48070946-166A59AA-17C1-40F9-9E95-67259F6351AA

Q48070946-1A04BE33-F118-4EC6-8931-F72315DBD99B

Q48070946-34DDFFAB-A7FD-41A9-87BE-6140ABB8FFAF

Q48070946-627F565E-41DA-4726-BA50-731C5CE110B5

Q48070946-65B24A79-D1CF-45A1-8BA8-A50ADBC8CE33

Q48070946-91A7E202-83D5-4FF7-901E-30751975EF38

Q48070946-F3CE57EB-A265-4D45-A378-CD4F6411DB9B

P2888

Q48070946-9AA80B3F-A46F-4D94-9F71-A4021E1C1B42

P304

Q48070946-D4557C02-5C0B-46F3-88C1-699D6EA9AC5F

P31

Q48070946-E95D8E23-D4C4-4E5F-A5E5-07DCCD102332

P356

Q48070946-028100C6-5089-4BE2-B42C-31D21DF297DA

P407

Q48070946-0C9A383E-EF1C-4513-B68C-756DBF337DBC

P433

Q48070946-EE8D3415-2805-4DF3-84F6-7AC24FA1DF9D

P478

Q48070946-CB90EBC7-7F1B-42E0-8189-287CB71188A7

P50

Q48070946-77440D77-3724-48F5-9D86-A34BBADF7652

P577

Q48070946-B90167F3-5E17-4252-8048-4128199ECD67

P6179

Q48070946-E72FB381-8CBA-428F-89F5-758A09219E11

P698

Q48070946-311A757E-4E0E-4976-839A-86DF0433F4AE

P356

P1433

P1476

Drug development: Illuminated targets

@en

P2093

Megan Cully

http://www.w3.org/2001/XMLSchema#string

P2860

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

Revisiting AMPA receptors as an antiepileptic drug target

The pharmacologic treatment of Dravet syndrome

Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels.

Brivaracetam for the treatment of epilepsy in adults.

Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment

Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.

P2888

P304

S12-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/511S12A

http://www.w3.org/2001/XMLSchema#string

P407

P433

7508

http://www.w3.org/2001/XMLSchema#string

P478

511

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1008646952

http://www.w3.org/2001/XMLSchema#string

P698

25019129

http://www.w3.org/2001/XMLSchema#string